ipharmacenter

#MSToronto2026 - Phase 3 #MultipleSclerosis data vs #teriflunomide: #Fenebrutinib: relapse rate 0.06 vs 0.13 #Remibrutinib: relapses reduced 35.2% and 31.2% ipharmacenter.com/post/ms-to… #news #breaking #neurology #MSToronto26 #ECTRIMS26 #ECTRIMS2026

Key #EADV2026 data readouts in #Dermatology: • IL-13, IL-31 & OX40/OX40L in AD • Oral DMARDs & IL-23/IL-17 in PsO • Topical/oral JAKi in Vitiligo & AA Full compilation of all congress abstracts & competitive intelligence: fiverr.com/ipharmacenter #ClinicalTrials #MarketAccess

Real-world DoD data (N=207) for $ABBV #upadacitinib in isolated ileal #CrohnsDisease: • Deep remission: 42.5% • Clinical remission: 57.0% • Endoscopic remission: 53.6% • Steroid drop: 86% ➔ 15.5% ipharmacenter.com/post/ameri… #ACG2026 #IBD #RWE

Phase 3 CROSSING: #Tezepelumab hits co-primary endpoints in #EoE at Wk24. • Remission: 68.9% (420mg) vs 3.5% (pbo) • DSQ Δ: -22.02 vs -14.73 • EREFS Δ: -3.65 vs -0.21 For full #ACG2026 abstract compilation, write to us fiverr.com/ipharmacenter #Pharma #Gastroenterology #ACG26

Johnson & Johnson $JNJ: Week-24 combined fistula remission with #Tremfya reached 28% and 27% across dosing groups vs 10% with placebo. ipharmacenter.com/post/ameri… #CrohnsDisease #IBD #ACG2026 #UlcerativeColitis #IBD #GITwitter

Johnson & Johnson $JNJ: Remisión combinada de fístulas a la semana 24: 28% y 27% con Tremfya, según la pauta, frente al 10% con placebo. ipharmacenter.com/post/ameri… #Crohn #EII #Tremfya #ACG2026

Johnson & Johnson $JNJ: Week-24 combined fistula remission with Tremfya reached 28% and 27% across dosing groups vs 10% with placebo. ipharmacenter.com/post/ameri… #CrohnsDisease #IBD #Tremfya #ACG2026

#AbbVie $ABBV: Endoskopische Remission in AFFIRM, Woche 24: 35,8% mit #Skyrizi versus 9,1% mit Placebo. ipharmacenter.com/post/ameri… #ACG2026 #MorbusCrohn

AbbVie $ABBV : dans AFFIRM, rémission endoscopique à 24 semaines : 35,8% sous Skyrizi contre 9,1% sous placebo. ipharmacenter.com/post/ameri… #ACG2026 #Crohn

#AbbVie $ABBV: En AFFIRM, la remisión endoscópica a la semana 24 fue del 35,8% con #Skyrizi frente al 9,1% con placebo. ipharmacenter.com/post/ameri… #ACG2026 #Crohn

#AbbVie $ABBV: Week-24 endoscopic remission in AFFIRM was 35.8% with #Skyrizi SC vs 9.1% with placebo. ipharmacenter.com/post/ameri… #ACG2026 #CrohnsDisease #IBD

På #EADV2026 fremlagde Merck Fase 2b-resultater for #tulisokibart (anti-TL1A) til moderat til svær #hidradenitissuppurativa: HiSCR50: 72 % (hver 2. uge) og 64 % (hver 4. uge) vs 35 % placebo ipharmacenter.com/post/europ… #Dermatologi #Merck #Immunologi #EADV26

Under #EADV2026 presenterade Merck Fas 2b-resultat för #tulisokibart (anti-TL1A) vid måttlig till svår #hidradenitissuppurativa: • HiSCR50: 72 % (varannan vecka) & 64 % (var 4:e vecka) vs 35 % placebo ipharmacenter.com/post/europ… #Dermatologi #Merck #Immunologi #EADV26

Op het #EADV2026 presenteerde Merck Fase 2b-resultaten voor #tulisokibart (anti-TL1A) bij matige tot ernstige #hidradenitissuppurativa: HiSCR50: 72% (q2w) & 64% (q4w) vs. 35% placebo ipharmacenter.com/post/europ… #Dermatologie #Merck #Immunologie #EADV26

Al congresso #EADV2026, Merck ha presentato i risultati di Fase 2b di #tulisokibart (anti-TL1A) nell'#idrosadenitesuppurativa da moderata a grave: HiSCR50: 72% (ogni 2 sett.) e 64% (ogni 4 sett.) vs 35% placebo ipharmacenter.com/post/europ… #Dermatologia #Merck #Immunologia #EADV26

Auf der #EADV2026 stellte Merck Phase-2b-Ergebnisse für #tulisokibart (Anti-TL1A) bei mittelschwerer bis schwerer #AcneInversa (#HidradenitisSuppurativa) vor: HiSCR50: 72 % (q2w) & 64 % (q4w) vs. 35 % Placebo ipharmacenter.com/post/europ… #Dermatologie #Immunologie #EADV26

À l'#EADV2026, Merck a présenté les résultats de Phase 2b du #tulisokibart (anti-TL1A) dans l'#hidradénitesuppurée modérée à sévère : HiSCR50 : 72 % (Q2S) et 64 % (Q4S) vs 35 % placebo ipharmacenter.com/post/europ… #Dermatologie #EssaisCliniques #Phase2b #Merck #Immunologie #EADV26

En el #EADV2026, Merck presentó los resultados de Fase 2b de #tulisokibart (anti-TL1A) en #hidradenitissupurativa moderada a grave: HiSCR50: 72% (c/2 sem) y 64% (c/4 sem) vs 35% placebo ipharmacenter.com/post/europ… #Dermatología #EnsayosClínicos #Fase2b #Merck #Inmunología #EADV26

At #EADV2026, Merck presented Ph2b results for #tulisokibart (anti-TL1A) in mod-to-severe #hidradenitissuppurativa: • HiSCR50: 72% (Q2W) & 64% (Q4W) vs 35% placebo ipharmacenter.com/post/europ… #Dermatology #ClinicalTrials #Phase2b #Merck #Immunology #EADV26

CARTITUDE-2試験の5年データ：単回の #Carvykti 投与により、早期再発 #多発性骨髄腫 患者の50%が維持療法なしで無増悪を維持（PFS中央値：60.5カ月） ipharmacenter.com/post/inter… #IMS2026 #ESMO26 #がん